Definium Therapeutics (NASDAQ:DFTX) Insider Mark Sullivan Sells 13,008 Shares of Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Mark Sullivan sold 13,008 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Definium Therapeutics Trading Up 0.4%

DFTX stock opened at $44.95 on Friday. The company has a market cap of $4.48 billion, a P/E ratio of -18.05 and a beta of 2.37. Definium Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.01. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average of $24.59 and a 200-day moving average of $19.36.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, equities research analysts expect that Definium Therapeutics, Inc. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

DFTX has been the topic of a number of analyst reports. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a research note on Monday. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an “outperform” rating in a report on Monday. HC Wainwright raised their target price on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Canaccord Genuity Group set a $60.00 price target on Definium Therapeutics in a research note on Monday. Finally, Oppenheimer set a $60.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $47.08.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Institutional Investors Weigh In On Definium Therapeutics

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Definium Therapeutics during the third quarter worth $107,000. Flagship Harbor Advisors LLC bought a new stake in Definium Therapeutics in the 4th quarter valued at $117,000. Finally, Caxton Associates LLP bought a new stake in Definium Therapeutics in the 3rd quarter valued at $126,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.